Searchable abstracts of presentations at key conferences in endocrinology

ea0084op-03-12 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Clinicopathological and epidemiological features of thyroid cancer patients intended to initiate systemic therapy

Minaldi Elisa , Esposito Gerardo , Giani Carlotta , Valerio Laura , Agate Laura , Molinaro Eleonora , Elisei Rossella

Objectives: The majority of patients with differentiated thyroid carcinoma (TC) have an excellent prognosis, with a 5-year survival rate of 98.3%, and only rarely reaches an advanced stage of disease. The present study aims to identify the clinicopathological and epidemiological features at the time of diagnosis of a group of patients who required to be treated with systemic therapy with tyrosine-kinase inhibitors (TKI).Methods: We retrospectively evalua...

ea0084ps1-03-26 | Thyroid Cancer CLINICAL 1 | ETA2022

Age as a prognostic factor in ata low and intermediate risk thyroid cancer patients

Maino Fabio , Botte Monica , Valerio Laura , Cartocci Alessandra , Grazia Castagna Maria

Background and Aim: American Thyroid Association (ATA) guidelines do not consider age at diagnosis of differentiated thyroid cancer (DTC) as a prognostic factor in the estimation of risk of recurrence and persistent disease. While age at diagnosis has already been assessed in high-risk patients, it remains to be established whether there is a correlation between age at diagnosis and long term outcome in DTC patients.Methods: We retrospectively evaluated ...

ea0063gp263 | Thyroid Nodules and Cancer 2 | ECE2019

Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience

Valerio Laura , Bottici Valeria , Matrone Antonio , Tacito Alessia , Romei Cristina , Piaggi Paolo , Elisei Rossella

Objectives: Vandetanib (V) is an important drug in the metastatic medullary thyroid cancer (MTC) treatment. The objective of this study was to evaluate the presence of predictors of V response, in short and long period, in locally advanced or metastatic MTC patients (pts).Methods: Seventy-nine locally advanced or metastatic MTC pts with progressive or symptomatic disease, referred to our Center between 2007 and 2018 and already treated surgically and wit...

ea0063p392 | Thyroid 1 | ECE2019

The presence of tall cells, even if

Matrone Antonio , Gambale Carla , Torregrossa Liborio , Valerio Laura , Molinaro Eleonora , Basolo Fulvio , Vitti Paolo , Elisei Rossella

Background: CV-PTC is often indolent with excellent long-term response, while TCV-PTC (≥50% of tall cells) have aggressive features and worse clinical behavior. Less is known about the clinical behavior of CV-PTC with tall cells <50% (TC/CV-PTC) that, so far, is considered as low risk tumor.Aim: To evaluate the histological presentation of CV-PTC, TC/CV-PTC, TCV-PTC and their clinical behavior after 6 years of follow up.M...

ea0092op-10-02 | Oral Session 10: Novel diagnostics in Thyroid cancer | ETA2023

Role of the telomere abnormalities and chromosome fragility on the risk of second malignant tumor in papillary thyroid cancer patients

Valerio Laura , Mattii Elisa , Cantara Silvia , Cartocci Alessandra , Maino Fabio , Grazia Castagna Maria

Objectives: Genomic instability play a role in cancer development through different mechanisms including chromosome fragility and in particular the altered telomere length (TL). Previous studies showed that the presence of short telomeres in the blood was associated with development of sporadic head and neck, bladder, lung, renal and breast cancer. In thyroid cancer, has been demonstrated that familial form of papillary thyroid cancer (FPTC) has shorter telomeres in blood leuk...

ea0084op-01-05 | Oral Session 1: Topic Highlights | ETA2022

Sarcopenia as a prognostic factor in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors

Dalmiglio Cristina , Brilli Lucia , Ciuoli Cristina , Sannino Ida , Maino Fabio , Valerio Laura , Cartocci Alessandra , Grazia Castagna Maria

Objective: Recent studies have shown that sarcopenia at cancer diagnosis is associated with a poor survival in patients with solid tumors. Up to now, few data are available among patients with advanced thyroid cancer, especially those treated with tyrosine kinase inhibitors (TKI). We retrospectively evaluated sarcopenia by Skeletal Muscle Index (SMI) in a cohort of advanced thyroid cancer patients before and during TKI treatment and investigated its association with treatment ...

ea0084op-09-44 | Oral Session 9: Thyroid Cancer Clinical | ETA2022

Dynamic risk stratification in long-term clinical outcome of papillary thyroid cancer patients

Valerio Laura , Maino Fabio , Dalmiglio Cristina , Brilli Lucia , Botte Monica , Dalmazio Gilda , Di Stefano Leonardo , Grazia Castagna Maria

Introduction and Objective: The initial assessment of differentiated thyroid cancer (DTC) patients is based on the American Thyroid Association (ATA) risk stratification criteria. Dynamic risk stratification (DRS) of DTC patients takes into consideration the response to initial treatment being reassessed at 1–2 years and revealed significant shifts in the risk categories of DTC patients. We aimed to evaluate the long-term outcome of papillary thyroid cancer (PTC) patients...

ea0090p115 | Endocrine-related Cancer | ECE2023

Hand-foot syndrome: a frequent but rarely severe adverse event in patients with thyroid cancer treated with lenvatinib

Minaldi Elisa , Cappagli Virginia , Giani Carlotta , Valerio Laura , Lorusso Loredana , Matrone Antonio , Gambale Carla , Prete Alessandro , Puleo Luciana , Bottici Valeria , Molinaro Eleonora , Agate Laura , Elisei Rossella

Introduction: Hand-foot syndrome (HFS), or palmo-plantar erythrodysplasia, is an adverse event related to lenvatinib therapy. In the clinical trial (SELECT study) HFS was reported in 32% of patients, but only 3% was grade ≥3. In real-life studies the frequency was variable: between 8 and 55%.Patients: We collected clinical and pathological data about 165 patients with thyroid cancer treated with lenvatinib, followed up between 2012 and 2022 at the ...

ea0092ps3-29-05 | Treatment 2 | ETA2023

Tailored mortality risk in stage I-II DTC patients by integrating ata stratification and response to initial therapy

Dalmiglio Cristina , Forleo Raffaella , Fralassi Noemi , Maino Fabio , Brilli Lucia , Valerio Laura , Trimarchi Andrea , Pilli Tania , Cartocci Alessandra , Grazia Castagna Maria

Objectives: AJCC/TNM staging system provides an estimate of mortality risk in differentiated thyroid cancer (DTC) patients and recent evidence showed that ATA risk stratification may improve the definition of this risk. We speculated that the integration of the response to the initial therapy (RIT) could better define the mortality risk.Methods: We retrospectively evaluated 891 consecutive DTC patients followed at the Section of Endocrinology, University...